ArticleJournal of translational autoimmunity2025
The clinical characteristics and treatment response of myasthenia gravis with positive thyroid peroxidase antibody or thyroid globulin antibody.
Article in Journal of translational autoimmunity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Myasthenia gravis (MG) frequently associates with thyroid peroxidase antibody (TPOAb) and thyroglobulin antibody (TgAb), indicating shared autoimmunity. This study investigated the impact of TPOAb/TgAb on MG severity and pathogenesis, to inform improved management. Methods: We retrospectively analyzed 144 MG patients (Jan 2022-Dec 2024), stratified into four groups by TPOAb/TgAb status. We compared demographic and clinical profiles, analyzed the effects of disease duration, stage, and onset age on TPOAb/TgAb titers, and evaluated treatment responses across groups. Results: Among 144 included patients, 55.6 % were thyroid antibody (TAb) - positive (TPOAb + TgAb-: 18.8 %; TgAb + TPOAb-: 9.7 %; TPOAb + TgAb+: 27.1 %). Median onset age was 61 years, 67.5 % were female. TPOAb + TgAb- MG primarily presented as MGFA I (70.4 %), initial onset (63.0 %), with low thymoma (3.7 %) and no TitinAb/RyRAb. TPOAb + TgAb + MG exhibited a severe phenotype: higher MGFA III (30.8 %), relapsed (71.8 % vs 50.0 % in TPOAb-TgAb-, P = 0.030), thymoma (43.6 %), and TitinAb/RyRAb positivity (43.6 %/25.6 %). TgAb titers were significantly higher in relapsed MG (P = 0.001). Both TPOAb + TgAb+ and TPOAb-TgAb- MG responded better to pyridostigmine 90 mg/day, TPOAb + TgAb + MG showed superior response to high-dose glucocorticoids (40-60 mg/day) compared to TPOAb-TgAb- (P = 0.006). However, multivariate analysis indicated TPOAb + TgAb + status itself was not an independent predictor (OR = 0.077, 95 % CI: 0.000-23.487; P = 0.380). Conclusions: This study demonstrates the clinical significance of TPOAb/TgAb in MG. TPOAb + TgAb + status identifies a clinical subgroup with a "triple-high" profile. TgAb may show potential as a disease activity biomarker. These findings inform precision treatment strategies, pending validation in large prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.